no prescription required

pick your language: United Kingdom España Deutschland France Sverige Danmark norwegian Nederland Polska Česká republika Portugal Ελλάδα Italia

We Accept

Currently Offline




My doctor prescribed me with Avodart. Such was a good decision but by doctor prescription the prices
are high. Luckily I found your generic products that present the same high quality and above all with
very low price. Amazing!
- - Peter R -


Test Results for Avodart (Dutasteride)

Avodart / Dutasteride Phase II FDA Hair Loss Study Results
It was released last month at the American Academy of Dermatology (AAD) meeting in San Francisco the results for one of the most promising treatments for hairloss in the FDA approval pipeline. Roger S. Rittmaster, MD, produced Phase II (small scale human studies) trial results for the new Glaxo-Wellcome drug Dutasteride (GI198745), a dual 5-alpha reductase inhibitor.

Hairloss is interconnected to the Dihydrotestosterone hormone (DHT), a male hormone produced when enzyme 5-alpha reductase transforms Testosterone into DHT. Propecia (hairloss medication), inhibits one of the two types of this enzyme which turns Testosterone into DHT. Dutasteride (Avodart)  blocks both types of the enzyme, proving to be more effective at hairloss treatment. According to Rittmaster, men with type I 5-alpha reductase enzyme but without type II 5-alpha reductase enzyme (the one DHT blocks) experience hairloss when receiving Testosterone injections. Rittmaster states that such helps to demonstrate that type I enzyme does not influence hairloss.

Early tests showed in San Francisco the Dutasteride's ability to block DHT in comparison to Finasteride and a placebo. The Phase II studies gathered 416 men (21-45 years old) with Norwood patterns III, IV, and V. The study was on for 6 months and was random and anonymous for the investigators. Proscar and Placebo were compared to Dutasteride (0.05, 0.1, 0.5, and 2.5mg dosage). Proscar (5mg form of Finasteride) was used as Propecia was not available at the start of the clinical trials.

The first results were related to IC50 values for Propecia vs. Dutasteride. The IC50 value is the concentration of the drug needed to produce a 50% inhibition. If you don't have a scientific knowledge, the figures below will not do you much, but it translates as very little Dutasteride is required to inhibit type 1 5-alpha reductase but very large amounts of Propecia are needed to do so. In regards to type 2 5-alpha reductase (the type Propecia is intended to block), even less Dutasteride is needed to block it than Propecia. In sum, small doses of Dutasteride grant an excellent inhibition of both types of the 5-alpha reductase enzyme.

Provided by: American Academy of Dermatology